III) Prospective study using gene-expression analysis to predict response to primary systemic treatment with sequential docetaxel followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC) in primary breast cancer:
Laufzeit: 01.01.2007 - 31.12.2008